Analyst Price Target is GBX 222.50
▲ +120.30% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Celadon Pharmaceuticals in the last 3 months. The average price target is GBX 222.50, with a high forecast of GBX 235 and a low forecast of GBX 210. The average price target represents a 120.30% upside from the last price of GBX 101.
Current Consensus is
The current consensus among 2 polled investment analysts is to buy stock in Celadon Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Celadon Pharmaceuticals Plc engages in the research, cultivation, manufacturing, and sale of cannabis-based medicines. The company primarily focuses on growing indoor hydroponic cannabis for use in medicinal products used to treat chronic pain, as well as autism spectrum disorders. Celadon Pharmaceuticals Plc was founded in 2018 and is headquartered in London, the United Kingdom.